A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response

Anna P. Durbin, Beth D. Kirkpatrick, Kristen K. Pierce, Marya P. Carmolli, Cecilia M. Tibery, Palmtama L. Grier, Noreen Hynes, Kari Opert, Adrienne P. Jarvis, Beulah P. Sabundayo, Benjamin D. McElvany, Eli A. Sendra, Catherine J. Larsson, Matthew Jo, Janece M. Lovchik, Catherine J. Luke, Mary C. Walsh, Ellen A. Fraser, Kanta Subbarao, Stephen S. Whitehead

Research output: Contribution to journalArticlepeer-review

37 Scopus citations

Abstract

The ideal dengue vaccine will provide protection against all serotypes of dengue virus and will be economical and uncomplicated in its administration. To determine the ability of a single dose of the live attenuated tetravalent dengue vaccine TV003 to induce a suitable neutralizing antibody response, a placebo-controlled clinical trial was performed in 48 healthy adults who received 2 doses of vaccine or placebo administered 12 months apart. Evaluation of safety, vaccine viremia, and neutralizing antibody response after each dose indicated that the first dose of vaccine was capable of preventing infection with the second dose, thus indicating that multiple doses are unnecessary.

Original languageEnglish (US)
Pages (from-to)832-835
Number of pages4
JournalJournal of Infectious Diseases
Volume214
Issue number6
DOIs
StatePublished - Sep 15 2016

Keywords

  • clinicaltrial
  • dengue vaccine
  • live attenuated tetravalent

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response'. Together they form a unique fingerprint.

Cite this